WHO: The Meningitis Vaccine Project – where we are today
9 December 2011
At the end of 2011, Cameroon, Chad and Nigeria are vaccinating more than 22 million individuals aged 1-29 years with the new meningococcal A conjugate vaccine, MenAfriVac, which has the potential to eliminate the leading cause of meningitis epidemics in Africa. In audio files (in French), four individuals closely involved either in the clinical trials for the vaccine, the organization of mass campaigns, or the health of those living in a rural community participating in the trials, talk about their work and the impact that the vaccine is expected to have on the health of people living in the meningitis belt: Doctor Marie-Pierre Preziosi (Responsible for research and development of meningitis vaccines, WHO, Geneva); Doctor Carol Tevi-Benissan (Responsible for logistics planning of meningitis vaccine campaigns, WHO, Geneva); Doctor Aldiouma Diallo (Principal Investigator, MenAfriVac clinical trials, Institut de recherche pour le développement (IRD), Niakhar, Senega); Doctor Seynabou Gaye (District Medical Officer of Niakhar, Sénégal).
vaccines and global health :: ethics and policy 